JP Morgan Downgrades Mereo BioPharma Group to Underweight
JP Morgan analyst Priyanka Grover downgrades Mereo BioPharma Group (NASDAQ:MREO) from Neutral to Underweight.
Read original at benzingaStocks · News reference
Mereo BioPharma Group Q2 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 11, 2026, 12:17 PM
- Checked
- Aug 11, 2026, 12:17 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Mereo BioPharma Group plc (MREO)
Filed: 2026-08-19 AccNo: 0001193125-26-356168 Size: 218 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Read original at edgar12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Dermata Therapeutics (NASDAQ:DRMA) stock moved upwards by 44.4% to $1.56 during Tuesday's after-market session. The company's market cap stands at $4.5 million. As per the news, the Q2 earnings report
Read original at benzinga12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release, Q2 earnings
Read original at benzinga